An announcement from NeuroBo Pharmaceuticals (NRBO) is now available.
NeuroBo Pharmaceuticals, Inc. has entered into an exclusive licensing agreement with MThera Pharma Co., Ltd. for the rights to NB-01, a treatment for painful diabetic neuropathy. The deal empowers MThera to conduct extensive research and potentially a Phase 3 clinical trial in the U.S. and South Korea. However, the press release also contains cautionary statements about forward-looking information, indicating that these projections are not assured and actual results could vary significantly.
Learn more about NRBO stock on TipRanks’ Stock Analysis page.
